ABSTRACT
PURPOSE: Evidence suggests that premenopausal obesity decreases and postmenopausal obesity increases breast cancer risk. Because it is not well known whether this is subtype dependent, we studied the association between body mass index (BMI) and age at breast cancer diagnosis, or the probability of being diagnosed with a specific breast cancer phenotype, by menopausal status. METHODS: All patients with non-metastatic operable breast cancer from the University Hospital Leuven diagnosed between January 1, 2000 and December 31, 2013 were included (n = 7020) in this cross-sectional study. Linear models and logistic regression were used for statistical analysis. Allowing correction for age-related BMI-increase, we used the age-adjusted BMI score which equals the difference between a patient's BMI score and the population-average BMI score corresponding to the patient's age category. RESULTS: The quadratic relationship between the age-adjusted BMI and age at breast cancer diagnosis (p = 0.0207) interacted with menopausal status (p < 0.0001); increased age at breast cancer diagnosis was observed with above-average BMI scores in postmenopausal women, and with below-average BMI scores in premenopausal women. BMI was linearly related to the probabilities of Luminal B and HER2-like breast cancer phenotypes, but only in postmenopausal women. The relative changes in probabilities between both these subtypes mirrored each other. CONCLUSION: BMI associates differently before and after menopause with age at breast cancer diagnosis and with the probability that breast cancer belongs to a certain phenotype. The opposite effect of increasing BMI on relative frequencies of Luminal B and HER2-like breast cancers suggests a common origin.
Subject(s)
Body Mass Index , Breast Neoplasms/pathology , Obesity/epidemiology , Postmenopause/metabolism , Premenopause/metabolism , Adult , Age Factors , Belgium , Breast/metabolism , Breast/pathology , Breast Neoplasms/diagnosis , Breast Neoplasms/metabolism , Cross-Sectional Studies , Female , Humans , Middle Aged , Obesity/diagnosis , Obesity/metabolism , Parity , Prospective Studies , Receptor, ErbB-2/metabolism , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Risk FactorsABSTRACT
BACKGROUND: Aromatase inhibitor (AI) therapy is associated with musculoskeletal (MS) toxicity, which adversely affects quality of life and therapy adherence. Our objective was to evaluate whether genetic variants may predict endocrine therapy-related MS pain and hot flashes in a prospective observational cohort study. PATIENTS & METHODS: 254 early breast cancer patients starting AI (n = 159) or tamoxifen therapy (n = 95) were included in this genetic biomarker study. MS and vasomotor symptoms were assessed at baseline and after 3, 6 and 12 months of therapy. AI-induced MS pain was defined as an increase in arthralgia or myalgia relative to baseline. Single nucleotide polymorphisms (SNP) in candidate genes involved in oestrogen signalling or previously associated with AI-related MS pain or oestrogen levels were selected. RESULTS: Overall, 13 SNPs in CYP19, CYP17, osteoprotegerin (OPG) and oestrogen receptor 1 exhibited an allele frequency >0.05 and were included in the analysis. Patients carrying the G allele of rs2073618 in OPG experienced significantly more AI-induced MS toxicity compared to the wildtype allele, after correction for multiple testing (P = 0.046). Furthermore, this SNP was associated with severity of pain (P = 0.018). No association was found with regard to the other SNPs, both in AI and tamoxifen-treated patients. Neither could an association with vasomotor symptoms be demonstrated. CONCLUSION: The SNP rs2073618 in OPG is associated with an increased risk of MS symptoms and pain with AI therapy, which has not been reported previously. Validation of this finding in larger cohorts and further functional studies are required.
Subject(s)
Antineoplastic Agents, Hormonal/adverse effects , Aromatase Inhibitors/adverse effects , Breast Neoplasms/drug therapy , Musculoskeletal Pain/chemically induced , Musculoskeletal Pain/genetics , Osteoprotegerin/genetics , Polymorphism, Single Nucleotide , Aged , Aged, 80 and over , Arthralgia/chemically induced , Arthralgia/genetics , Breast Neoplasms/enzymology , Female , Genetic Association Studies , Genetic Predisposition to Disease , Humans , Longitudinal Studies , Middle Aged , Musculoskeletal Pain/diagnosis , Myalgia/chemically induced , Myalgia/genetics , Pain Measurement , Phenotype , Prospective Studies , Risk Factors , Time FactorsABSTRACT
Aromatase inhibitor (AI) therapy for estrogen receptor-positive breast cancer is known to induce or enhance musculoskeletal problems. We have previously reported that loss of grip strength is more pronounced in AI-users with extremes in BMI. We here report results from a larger prospective study. Postmenopausal early breast cancer patients scheduled to start AI or tamoxifen therapy were recruited. A functional assessment grip strength test was performed at baseline, 3, 6, and 12 months of therapy. BMI was assessed, and a rheumatologic questionnaire was completed at each visit. 188 patients on an AI and 104 patients on tamoxifen were enrolled. 74 % of AI-users reported new/worsened musculoskeletal complaints compared with 37 % in the tamoxifen group. This was translated in a larger grip strength decrease in patients experiencing AI-induced pain opposed to patients without new/worsened complaints (p = 0.0002). 15 % of AI-users discontinued therapy due to musculoskeletal symptoms, who were characterized by a larger grip strength reduction versus adherent patients (p = 0.0107). Young age (p = 0.0135), taxane-based chemotherapy (p = 0.0223), and baseline VAS score >4 (p = 0.0155) were predictors for AI-related musculoskeletal pain. In addition, a quadratic trend of BMI with grip strength change (p = 0.0090) and probability of discontinuation was observed (p = 0.0424). Musculoskeletal events were a substantial problem in AI-treated patients and an important reason for treatment discontinuation. The decrease in grip strength was larger in AI- than in tamoxifen-users, with a more pronounced change in symptomatic patients. The inverse relationship between BMI extremes and grip strength change was confirmed in this large group of AI-patients.
Subject(s)
Antineoplastic Agents, Hormonal/adverse effects , Aromatase Inhibitors/adverse effects , Breast Neoplasms/complications , Breast Neoplasms/drug therapy , Hand Strength , Musculoskeletal Diseases/etiology , Tamoxifen/adverse effects , Aged , Aged, 80 and over , Antineoplastic Agents, Hormonal/therapeutic use , Aromatase Inhibitors/therapeutic use , Body Mass Index , Breast Neoplasms/pathology , Chemoradiotherapy, Adjuvant/adverse effects , Female , Humans , Medication Adherence , Middle Aged , Musculoskeletal Diseases/diagnosis , Musculoskeletal Diseases/drug therapy , Musculoskeletal Pain/etiology , Neoplasm Grading , Neoplasm Metastasis , Neoplasm Staging , Postmenopause , Prospective Studies , Risk Factors , Surveys and Questionnaires , Tamoxifen/therapeutic useABSTRACT
The occupational therapy department of the University Hospital of Leiden treats a relatively large number of children, born with a dysmelia of the forearm. This article has been written to give information about the possibilities to supply these children with a prosthesis, and how this effects their level of independence. A short description of occupational therapy and the working of a myoelectric prosthesis will be followed by a case-study of a boy with plural congenital reduction defects. He needs several prosthesis and aids to become (mainly) independent of the help from others. It will be described how aids are made and tested, and how the prosthesis is used. The case-study illustrates that the different demands and desires which are demanded from prosthesis and aids, are related to the age and developmental level of the child.